Wednesday, May 16, 2018 11:39:32 AM
The calm before the storm. A huge storm is coming. The SP will be moving dramatically any day now. The question is which way? It seems that everyone is content to ride out the status quo until we know. Holders aren't selling. Watchers aren't buying. Everyone is waiting.
So, what are we waiting for?
The offering. What price and how many shares? An offering at $10 per share for 2M shares to raise $20M would be awesome! Not likely, but awesome!
An offering at $1.00 for 20M shares to raise $20M would be a bit different. After the offering was completed, the company would have cash to carry them through for a year or so. This would get them close to FDA approval, IMO. The OS would only be 21M. The long-term effect of even that scenario looks good.
I believe these are the two extremes at this point. So, the long-term prognosis looks pretty good to me at this point. The short term is very questionable at this point.
Also, uplisting to NASDAQ is a very likely possibility.
So, let the waiting game continue. Action is coming soon.
So, what are we waiting for?
The offering. What price and how many shares? An offering at $10 per share for 2M shares to raise $20M would be awesome! Not likely, but awesome!
An offering at $1.00 for 20M shares to raise $20M would be a bit different. After the offering was completed, the company would have cash to carry them through for a year or so. This would get them close to FDA approval, IMO. The OS would only be 21M. The long-term effect of even that scenario looks good.
I believe these are the two extremes at this point. So, the long-term prognosis looks pretty good to me at this point. The short term is very questionable at this point.
Also, uplisting to NASDAQ is a very likely possibility.
So, let the waiting game continue. Action is coming soon.
Recent DCTH News
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2025 Results • Business Wire • 02/26/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:05 AM
- Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call • Business Wire • 02/12/2026 01:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/10/2026 07:41:34 PM
- Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference • Business Wire • 01/27/2026 01:05:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/21/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 09:41:41 PM
- Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 01/09/2026 01:05:00 PM
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma • Business Wire • 12/31/2025 01:00:00 PM
